dailiport hart forðahylki 1 mg
sandoz a/s - tacrolimusum mónohýdrat - hart forðahylki - 1 mg
dailiport hart forðahylki 2 mg
sandoz a/s - tacrolimusum mónohýdrat - hart forðahylki - 2 mg
dailiport hart forðahylki 3 mg
sandoz a/s - tacrolimusum mónohýdrat - hart forðahylki - 3 mg
zinacef stungulyfs-/innrennslisstofn, lausn 1,5 g
sandoz a/s - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 1,5 g
zinacef stungulyfs-/innrennslisstofn, lausn 750 mg
sandoz a/s - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 750 mg
zofran filmuhúðuð tafla 4 mg
sandoz a/s - ondansetronum hýdróklóríð - filmuhúðuð tafla - 4 mg
zofran filmuhúðuð tafla 8 mg
sandoz a/s - ondansetronum hýdróklóríð - filmuhúðuð tafla - 8 mg
zofran mixtúra, lausn 0,8 mg/ml
sandoz a/s - ondansetronum hýdróklóríð - mixtúra, lausn - 0,8 mg/ml
tyruko
sandoz gmbh - natalízúmab - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ónæmisbælandi lyf - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
herwenda
sandoz gmbh - trastuzúmab - breast neoplasms; stomach neoplasms - Æxlishemjandi lyf - treatment of metastatic and early breast cancer and metastatic gastric cancer (mgc).